Response to “Comment on ‘IARC Workshop on the Key Characteristics of Carcinogens: Assessment of End Points for Evaluating Mechanistic Evidence of Carcinogenic Hazards’” Authors: David M. DeMarini, Weihsueh A. Chiu, Kathryn Z. Guyton, William Gwinn, Brad Reisfeld, Amy Wang, Aline de Conti, Mary K. Schubauer-Berigan, Federica Madia Published: 2026 The key characteristics (KCs) framework was developed during a comprehensive review of the carcinogenic mechanisms for established human carcinogens that were re-evaluated in IARC [International Agency for Cancer Research] Monographs volume 100, , and the 10 KCs reflect the major chemical and biological properties of these agents. , The framework, reinforced by subsequent publications, , supports a systematic and transparent approach to reviewing and synthesizing the literature, avoiding bias toward a favored mechanism. , Furthermore, the framework has been recommended by the US National Academies as a rigorous methodology for incorporating mechanistic evidence into hazard and risk assessment. Our commentary described a recent IARC Scientific Workshop focused on interpretation of mechanistic end points, incorporation of emerging assays and biomarkers, and integration of mechanistic evidence. Goodman et al. raise some issues with our article, including that “induces oxidative stress” (KC5) and “is genotoxic” (KC2) should not be used alone to establish “strong” mechanistic evidence within the IARC classification system. They further assert that evidence on KCs should not be used to distinguish probable (Group 2A) or possible (Group 2B) human carcinogens from non-carcinogenic agents. We appreciate the opportunity to provide clarifications in response. The 2019 Preamble to the IARC Monographs states, “Because non-carcinogens can also induce oxidative stress, this KC [i.e., KC5, “induces oxidative stress”] should be interpreted with caution unless it is found in combination with other KCs.” Furthermore, it states that “evidence for a group of KCs can strengthen mechanistic conclusions,” which applies to agents that are genotoxic. Additionally, the IARC Preamble provides clear distinction in the strengths of evidence between Groups 2A, 2B, and 3 , (Figure ). Group 2B is used when there is only a single stream of evidence (cancer in humans, cancer in experimental animals, or mechanistic evidence) supporting the classification. By contrast, evidence on the KCs cannot alone be used to classify an agent in Group 2A. For example, in IARC Monographs volume 128, crotonaldehyde and arecoline were classified in Group 2B based solely on evidence for multiple KCs whereas acrolein was classified in Group 2A because there was “sufficient” evidence for cancer in experimental animals in addition to “strong” mechanistic evidence from several KCs, including evidence of DNA adducts in exposed humans. Group 2A may also be reached through membership in a mechanistic class alone, based on evidence beyond the KCs, including considerations of chemical structure and biological activity, metabolism, and animal tumor site concordance, as seen in volumes 125 and 127 for various chemical agents. Overview of evidence integration leading to overall evaluations in the IARC Monographs program (adapted from IARC, 2019). In summary, Goodman et al. are mistaken to imply that the KCs represent a “checklist” or diminish the distinction between agents. The IARC Preamble and its KCs framework provide a systematic and transparent method of assembling and synthesizing mechanistic data for cancer hazard identification, characterizing the strength of the available mechanistic evidence, identifying gaps in the evidence, and facilitating integration with other streams of evidence. The utility of the KCs approach is underscored by its increasing application by various agencies, including the US Environmental Protection Agency and US National Toxicology Program, in a variety of contexts. −